A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.

See ANZCTR for full trial details >

 

Trial Summary:

To determine and compare the efficacy and tolerability between the three treatment arms across study patients, in particular, 36 week progression-free survival rate.

Supported By:

Astra Zeneca

Eligibility:

Women 18 years and over with asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.

Registration ID:

ACTRN12618000686202

Participation:

Australia

Australian Lead Group:

ANZGOG

Status:

Recruiting

Activation Date:

01.02.2019

Chairs:

Prof Clare Scott

Contact:

solace2@ctc.usyd.edu.au